TITLE

Immune System Targets Cancer

PUB. DATE
October 2009
SOURCE
Current Science;10/2/2009, Vol. 95 Issue 3, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the relevance of the use of immunotherapy in treating neuroblastoma based on the medical case of seven year old patient Brian Mullin.
ACCESSION #
44479819

 

Related Articles

  • Immunotherapy Add-on Boosts Survival.  // BioWorld Today;10/4/2010, Vol. 21 Issue 191, Special section p2 

    The article discusses research on the efficacy of immunotherapy in improving the survival of children with neuroblastoma, published in "The New England Journal of Medicine."

  • Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan. Modak, Shakeel; Kushner, Brian H.; Kramer, Kim; Vickers, Andrew; Irene Y. Cheung; Nai-Kong V. Cheung // OncoImmunology;Mar2013, Vol. 2 Issue 3, pe23402-1 

    β-glucans are complex, naturally-occurring polysaccharides that prime leukocyte dectin and complement receptor 3. Based on our preclinical findings, indicating that oral barley-derived (1 → 3),(1 → 4)-β-D-glucan (BG) synergizes with the murine anti-GD2 antibody 3F8 against...

  • Development of treatment strategies for advanced neuroblastoma. Hara, Junichi // International Journal of Clinical Oncology;Jun2012, Vol. 17 Issue 3, p196 

    Neuroblastoma is the most common cancer in childhood. The majority of patients with neuroblastoma are assigned to the high-risk group based on age at diagnosis, stage, histology, MYCN status, and DNA ploidy. Their prognosis remains unsatisfactory; the 5-year event-free survival (EFS) rate is...

  • At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. Moreno, Lucas; Marshall, Lynley V.; Pearson, Andrew D.J. // British Medical Bulletin; 

    Introduction Neuroblastoma is one of the commonest and deadliest forms of childhood cancer and major initiatives are ongoing to improve the outcome of these patients. Sources of data Data for this review were obtained from PubMed and abstracts from the American Society of Clinical Oncology and...

  • Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response. Lode, Holger; Schmidt, Manuela; Seidel, Diana; Huebener, Nicole; Brackrock, Diana; Bleeke, Matthias; Reker, Daniel; Brandt, Sven; Mueller, Hans-Peter; Helm, Christiane; Siebert, Nikolai // Cancer Immunology, Immunotherapy;Jun2013, Vol. 62 Issue 6, p999 

    Purpose: Immunotherapy targeting disialoganglioside GD emerges as an important treatment option for neuroblastoma, a pediatric malignancy characterized by poor outcome. Here, we report the induction of a GD-specific immune response with ganglidiomab, a new anti-idiotype antibody to anti-GD...

  • A victory over kids' cancer. Ozkaynak, M. Fevzi // Fairfield County Business Journal;9/7/2009, Vol. 48 Issue 36, Special section p4 

    The article reports on a treatment of neuroblastoma, a cancer which causes 15 percent of deaths among children. It notes that Dr. M. Fevzi Ozkaynak of Maria Fareri Children's Hospital at Westchester Medical Center in New York has devised an immunotherapy treatment to cure the cancer. It mentions...

  • The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Soto, Brenda; Hank, Jacquelyn; Voort, Tyler; Subramanian, Lalita; Polans, Arthur; Rakhmilevich, Alexander; Yang, Richard; Seo, Songwong; Kim, KyungMann; Reisfeld, Ralph; Gillies, Stephen; Sondel, Paul // Cancer Immunology, Immunotherapy;May2011, Vol. 60 Issue 5, p731 

    We investigated the anti-tumor effect of peritumoral resveratrol in combination with immunotherapy in vivo in neuroblastoma-bearing mice. Subcutaneous NXS2 tumors were induced in A/J mice. On day 10, some mice received 15 mcg of intravenous immunocytokine for 5 days, mice received 20 mg of...

  • Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood. Chowdhury, Ferdousi; Lode, Holger; Cragg, Mark; Glennie, Martin; Gray, Juliet // Cancer Immunology, Immunotherapy;Jun2014, Vol. 63 Issue 6, p559 

    Neuroblastoma, a childhood tumour of neuroectodermal origin, accounts for 15 % of paediatric cancer deaths, which is often metastatic at diagnosis and despite aggressive therapies, it has poor long-term prognosis with high risk of recurrence. Monoclonal antibody (mAb) therapy targeting GD2, a...

  • Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity. Rigo, Valentina; Corrias, Maria; Orengo, Anna; Brizzolara, Antonella; Emionite, Laura; Fenoglio, Daniela; Filaci, Gilberto; Croce, Michela; Ferrini, Silvano // Cancer Immunology, Immunotherapy;May2014, Vol. 63 Issue 5, p501 

    IL-21 is an immune-enhancing cytokine, which showed promising results in cancer immunotherapy. We previously observed that the administration of anti-CD4 cell-depleting antibody strongly enhanced the anti-tumor effects of an IL-21-engineered neuroblastoma (NB) cell vaccine. Here, we studied the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics